Adalimumab is a fully human monoclonal antibody that targets TNF-alpha and is also indicated for the treatment of six immune-mediated inflammatory diseases: rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), psoriasis (Ps) and Crohn's disease (CD) [37-52]. The gene discussed is TNF; the disease is ankylosing spondylitis.